Aeolus Pharmaceuticals (AOLS.OB) Appoints Russell Skibsted as Chief Financial Officer
Aeolus Pharmaceuticals is developing a new class of catalytic antioxidant compounds that protect healthy tissue from the damaging effects of radiation. The company's first compound, AEOL 10150, is being developed for oncology uses, in combination with radiation therapy. It is also being developed, with funding from the US government as a medical countermeasure against chemical and radiological weapons. The company today announced the appointment of Russell L. Skibsted as senior vice-president and chief financial officer. Mr. Skibsted is a seasoned executive with over 25 years of experience in finance, acquisitions, partnering, marketing and operations. He has worked with companies of…